Treatment of Multidrug Resistant Advanced Alveolar Soft Part Sarcoma With Sunitinib

• DOI: 10.1097/mjt.0b013e3181e70d20
• Publication Date: 2010-07-15T13:14:43Z
• Authors: Abhimanyu Ghose; Zeeshan Tariq; Salvatore Veltri
• Keywords: Adult; Male; Indoles; Lung Neoplasms; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Multiple; 3. Good health; 03 medical and health sciences; Sarcoma, Alveolar Soft Part; Treatment Outcome; 0302 clinical medicine; Drug Resistance, Neoplasm; Quality of Life; Sunitinib; Humans; Pyrroles

Sunitinib is a tyrosine kinase/angiogenesis inhibitor with proven efficacy in gastrointestinal stromal tumor and advanced renal cell carcinoma. We are presenting the case report of patient aggressive alveolar soft part sarcoma lung bone metastases, who had failed multiple chemotherapy regimens showing significant response to sunitinib. There was not only complete regression primary tumor, stabilization his metastases improvement quality life. Our shows that sunitinib has capability playing pivotal role management non-gastrointestinal tumors like sarcoma. Further research trials must be encouraged over use this drug as it most definitely promising.